{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:26:25Z","timestamp":1782174385234,"version":"3.54.5"},"reference-count":65,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102616\/Z (CONBRIO project)"],"award-info":[{"award-number":["102616\/Z (CONBRIO project)"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Gabapentin has been extensively prescribed off-label for psychiatric indications, with little established evidence of efficacy. Gabapentin and pregabalin, a very similar drug with the same mechanism of action, bind to a subunit of voltage-dependent calcium channels which are implicated in the aetiopathogenesis of bipolar disorder, anxiety and insomnia. This systematic review and meta-analysis aims to collect and critically appraise all the available evidence about the efficacy and tolerability of gabapentin and pregabalin in the treatment of bipolar disorder, insomnia and anxiety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia. For consideration of adverse effects (tolerability), single-blind or open-label RCTs and non-randomised evidence will also be summarised. The main outcomes will be efficacy (measured as dichotomous and continuous outcome) and acceptability (proportion of patients who dropped out of the allocated treatment). Published and unpublished studies will be sought through relevant database searches, trial registries and websites; all reference selection and data extraction will be conducted by at least 2 independent reviewers. We will conduct a random-effects meta-analysis to synthesise all evidence for each outcome. Heterogeneity between studies will be investigated by the I<jats:sup>2<\/jats:sup> statistic. Data from included studies will be entered into a funnel plot for investigation of small-study effects. No subgroup analysis will be undertaken, but we will carry out sensitivity analyses about combination treatment, psychiatric comorbidity, use of rescue medications and fixed versus random-effects model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This review does not require ethical approval. This protocol has been registered on PROSPERO (CRD42016041802). The results of the systematic review will be disseminated via publication in a peer-reviewed journal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013433","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T20:23:18Z","timestamp":1490646198000},"page":"e013433","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"7","author":[{"given":"Kerensa T","family":"Houghton","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Forrest","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Z","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stockton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Geddes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-8321","authenticated-orcid":false,"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK"},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"key":"2025101814330655000_7.3.e013433.1","first-page":"559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"Mack","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"2025101814330655000_7.3.e013433.2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199603000-00010"},{"key":"2025101814330655000_7.3.e013433.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701320"},{"key":"2025101814330655000_7.3.e013433.4","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199801000-00022"},{"key":"2025101814330655000_7.3.e013433.5","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200704280"},{"key":"2025101814330655000_7.3.e013433.6","unstructured":"Food and Drug Administration. Drug and New Biologic Approvals in 2004. Document. http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/drugandbiologicapprovalreports\/ucm081677.htm (accessed on 14 Apr 2016)."},{"key":"2025101814330655000_7.3.e013433.7","unstructured":"Food and Drug Administration. Efficacy Supplement Approvals in 2005. Document. http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/drugandbiologicapprovalreports\/ucm081892.htm (accessed 14 Apr 2016)."},{"key":"2025101814330655000_7.3.e013433.8","unstructured":"British National Formulary. Joint Formulary Committee. British National Formulary (online). http:\/\/www.evidence.nhs.uk\/formulary\/bnf\/current\/4-central-nervous-system\/48-antiepileptic-drugs\/481-control-of-the-epilepsies\/gabapentin-and-pregabalin (accessed 11 Jul 2016)."},{"key":"2025101814330655000_7.3.e013433.9","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2015-000639.501"},{"key":"2025101814330655000_7.3.e013433.10","first-page":"266","article-title":"Gabapentin use in a managed Medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"2025101814330655000_7.3.e013433.11","first-page":"5","article-title":"Gabapentin therapy in psychiatric disorders: a systematic review","volume":"17","author":"Berlin","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"2025101814330655000_7.3.e013433.12","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.20305.x"},{"key":"2025101814330655000_7.3.e013433.13","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00004"},{"key":"2025101814330655000_7.3.e013433.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01206-9"},{"key":"2025101814330655000_7.3.e013433.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60873-8"},{"key":"2025101814330655000_7.3.e013433.16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0320"},{"key":"2025101814330655000_7.3.e013433.17","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00010"},{"key":"2025101814330655000_7.3.e013433.18","first-page":"36","article-title":"Drug maker to pay $430 million in fines, civil damages","volume":"38","author":"Food and Drug Administration","year":"2004","journal-title":"FDA Consum"},{"key":"2025101814330655000_7.3.e013433.19","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.185"},{"key":"2025101814330655000_7.3.e013433.20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jad.2012.09.005","article-title":"An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder","volume":"147","author":"Schaffer","year":"2013","journal-title":"J Affect Disord"},{"key":"2025101814330655000_7.3.e013433.21","first-page":"261","article-title":"Antiepileptics from \u03b3-aminobutyric acid","volume":"44","author":"Satzinger","year":"1994","journal-title":"Drug Res"},{"key":"2025101814330655000_7.3.e013433.22","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.CR0050020"},{"key":"2025101814330655000_7.3.e013433.23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"key":"2025101814330655000_7.3.e013433.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.12.084"},{"key":"2025101814330655000_7.3.e013433.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409066103"},{"key":"2025101814330655000_7.3.e013433.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.03.002"},{"key":"2025101814330655000_7.3.e013433.27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.16.1.521"},{"key":"2025101814330655000_7.3.e013433.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2009.06.006"},{"key":"2025101814330655000_7.3.e013433.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(03)00066-7"},{"key":"2025101814330655000_7.3.e013433.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)81057-0"},{"key":"2025101814330655000_7.3.e013433.31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.209"},{"key":"2025101814330655000_7.3.e013433.32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002151"},{"key":"2025101814330655000_7.3.e013433.33","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.96"},{"key":"2025101814330655000_7.3.e013433.34","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.143"},{"key":"2025101814330655000_7.3.e013433.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00125-8"},{"key":"2025101814330655000_7.3.e013433.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00056-8"},{"key":"2025101814330655000_7.3.e013433.37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001711"},{"key":"2025101814330655000_7.3.e013433.38","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/mp.2016.86","article-title":"A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development","volume":"21","author":"Cipriani","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"(6 Suppl 5)","key":"2025101814330655000_7.3.e013433.39","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology"},{"issue":"(Suppl 6)","key":"2025101814330655000_7.3.e013433.40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"2025101814330655000_7.3.e013433.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708930105"},{"key":"2025101814330655000_7.3.e013433.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature11033"},{"key":"2025101814330655000_7.3.e013433.43","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.32168"},{"key":"2025101814330655000_7.3.e013433.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-010-0862-z"},{"key":"2025101814330655000_7.3.e013433.45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.5665\/sleep.4972","article-title":"Cacna1c (Cav1. 2) modulates electroencephalographic rhythm and rapid eye movement sleep recovery","volume":"38","author":"Kumar","year":"2015","journal-title":"Sleep"},{"key":"2025101814330655000_7.3.e013433.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)02002-6"},{"key":"2025101814330655000_7.3.e013433.47","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318254e6fd"},{"key":"2025101814330655000_7.3.e013433.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.01.040"},{"key":"2025101814330655000_7.3.e013433.49","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08010077"},{"key":"2025101814330655000_7.3.e013433.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2010.04.035"},{"key":"2025101814330655000_7.3.e013433.51","first-page":"133","article-title":"The role of GABA in the pathophysiology and treatment of anxiety disorders","volume":"37","author":"Nemeroff","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"2025101814330655000_7.3.e013433.52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/nyas.13048","article-title":"Innovative approaches to bipolar disorder and its treatment","volume":"1366","author":"Harrison","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"2025101814330655000_7.3.e013433.53","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12223"},{"key":"2025101814330655000_7.3.e013433.54","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)70314-1"},{"key":"2025101814330655000_7.3.e013433.55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3646"},{"key":"2025101814330655000_7.3.e013433.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60750-2"},{"key":"2025101814330655000_7.3.e013433.57","unstructured":"National Collaborating Centre for Mental Health. Generalised anxiety disorder and panic disorder in adults: management. https:\/\/www.nice.org.uk\/guidance\/cg113 (accessed 5 Jan 2017)."},{"key":"2025101814330655000_7.3.e013433.58","unstructured":"Higgins JPT , Green S , eds. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http:\/\/handbook.cochrane.org"},{"key":"2025101814330655000_7.3.e013433.59","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2014-101900"},{"key":"2025101814330655000_7.3.e013433.60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7066.1200"},{"key":"2025101814330655000_7.3.e013433.61","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2014-101795"},{"key":"2025101814330655000_7.3.e013433.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025101814330655000_7.3.e013433.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"2025101814330655000_7.3.e013433.64","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2013-101700"},{"key":"2025101814330655000_7.3.e013433.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:33:17Z","timestamp":1760823197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,27]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1136\/bmjopen-2016-013433"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013433","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}